Nov. 11, 2004 – Austin, Texas-based Introgen Therapeutics Inc. said animal trials of its nanoparticle-based therapy have shown significant suppression of tumor growth and prolonged survival of mice with lung cancer, according to a news release.
University of Texas medical researchers found that direct injection of INGN 401, a nanoparticle formulation of the tumor suppressor gene FUS1, not only suppressed tumor growth but also led to tumor regression in some animals. Trial data also showed that the therapy inhibited the spread of cancer and extended the life of treated mice by nearly 70 percent, the release said.
Data from the animal studies appears in the current issue of Cancer Gene Therapy. INGN 401 has begun human trials in patients with lung cancer and initial survival results are encouraging, the release said.